Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol

Antonio Molino, Giovanna Calabrese, Mauro Maniscalco

Research output: Contribution to journalReview article

Abstract

The pharmacological treatment for stable COPD is based on the use of inhaled bronchodilators (long-acting muscarinic receptor antagonists and long-acting beta-2 adrenoceptor agonists) and inhaled corticosteroids. The use of triple inhaled therapy is recommended to selected patients with COPD. Among the various inhaler combinations in triple therapy, a new combination by fluticasone furoate, umeclidinium, and vilanterol is available for COPD patients. Recently, a large clinical trial using this combination has been published, resulting in a reduction in exacerbation rate in COPD patients. Furthermore, this combination has demonstrated efficacy and safety, with a single administration a day, through a dry powder inhalator device, which has shown a good adherence and is a preference of the patient. This review focuses on the main characteristics of this inhaler combination evaluating the main clinical effects, the patients' adherence, and the safety.

Original languageEnglish
Pages (from-to)993-1001
Number of pages9
JournalPatient Preference and Adherence
Volume12
DOIs
Publication statusPublished - 2018

Fingerprint

Nebulizers and Vaporizers
Chronic Obstructive Pulmonary Disease
Muscarinic Antagonists
Patient Preference
Bronchodilator Agents
Muscarinic Receptors
Therapeutics
Patient Safety
Patient Compliance
Powders
Adrenergic Receptors
Adrenal Cortex Hormones
Clinical Trials
Pharmacology
Safety
Equipment and Supplies
GSK573719
vilanterol
fluticasone furoate

Cite this

Patient considerations in the treatment of COPD : focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol. / Molino, Antonio; Calabrese, Giovanna; Maniscalco, Mauro.

In: Patient Preference and Adherence, Vol. 12, 2018, p. 993-1001.

Research output: Contribution to journalReview article

@article{30bf0eeda9a844748c1b640762fc9ce4,
title = "Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol",
abstract = "The pharmacological treatment for stable COPD is based on the use of inhaled bronchodilators (long-acting muscarinic receptor antagonists and long-acting beta-2 adrenoceptor agonists) and inhaled corticosteroids. The use of triple inhaled therapy is recommended to selected patients with COPD. Among the various inhaler combinations in triple therapy, a new combination by fluticasone furoate, umeclidinium, and vilanterol is available for COPD patients. Recently, a large clinical trial using this combination has been published, resulting in a reduction in exacerbation rate in COPD patients. Furthermore, this combination has demonstrated efficacy and safety, with a single administration a day, through a dry powder inhalator device, which has shown a good adherence and is a preference of the patient. This review focuses on the main characteristics of this inhaler combination evaluating the main clinical effects, the patients' adherence, and the safety.",
author = "Antonio Molino and Giovanna Calabrese and Mauro Maniscalco",
year = "2018",
doi = "10.2147/PPA.S152179",
language = "English",
volume = "12",
pages = "993--1001",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Patient considerations in the treatment of COPD

T2 - focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol

AU - Molino, Antonio

AU - Calabrese, Giovanna

AU - Maniscalco, Mauro

PY - 2018

Y1 - 2018

N2 - The pharmacological treatment for stable COPD is based on the use of inhaled bronchodilators (long-acting muscarinic receptor antagonists and long-acting beta-2 adrenoceptor agonists) and inhaled corticosteroids. The use of triple inhaled therapy is recommended to selected patients with COPD. Among the various inhaler combinations in triple therapy, a new combination by fluticasone furoate, umeclidinium, and vilanterol is available for COPD patients. Recently, a large clinical trial using this combination has been published, resulting in a reduction in exacerbation rate in COPD patients. Furthermore, this combination has demonstrated efficacy and safety, with a single administration a day, through a dry powder inhalator device, which has shown a good adherence and is a preference of the patient. This review focuses on the main characteristics of this inhaler combination evaluating the main clinical effects, the patients' adherence, and the safety.

AB - The pharmacological treatment for stable COPD is based on the use of inhaled bronchodilators (long-acting muscarinic receptor antagonists and long-acting beta-2 adrenoceptor agonists) and inhaled corticosteroids. The use of triple inhaled therapy is recommended to selected patients with COPD. Among the various inhaler combinations in triple therapy, a new combination by fluticasone furoate, umeclidinium, and vilanterol is available for COPD patients. Recently, a large clinical trial using this combination has been published, resulting in a reduction in exacerbation rate in COPD patients. Furthermore, this combination has demonstrated efficacy and safety, with a single administration a day, through a dry powder inhalator device, which has shown a good adherence and is a preference of the patient. This review focuses on the main characteristics of this inhaler combination evaluating the main clinical effects, the patients' adherence, and the safety.

U2 - 10.2147/PPA.S152179

DO - 10.2147/PPA.S152179

M3 - Review article

C2 - 29922045

VL - 12

SP - 993

EP - 1001

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -